NeuroBLAST

NeuroBLAST operates in medical devices, rehabilitation, and digital health, with a focus on home-based neurological rehabilitation between clinical sessions. Its Motus device tracks supported hand, arm, and leg movements, while Aequa measures balance and weight shifts; the company combines both with a custom tablet and game-based activities. The relevant competitive field includes providers of rehabilitation devices, digital therapy programs, and connected home exercise systems. NeuroBLAST’s stated differentiation is the pairing of motion tracking and pressure-sensing balance practice in one home-oriented system, alongside clinical input and product certification milestones including CE MDR, FCC, and RoHS. The company is based in Belgrade and has a reported team size of 1–10 employees, suggesting a small-scale position within this broader health technology market.

NeuroBLAST was founded in 2021 and has developed a connected rehabilitation offering around two devices: Motus for movement tracking and Aequa for balance training. Its visible funding history begins with a €600,000 pre-seed round led by Katapult Accelerator in 2023, followed by a €300,000 seed extension recorded in 2024. On Jan 29, 2025, the company received non-equity assistance from MBRIF, and later that year it was recognized at MBRIF’s Cohort 9 Demo Day with the Most Impactful Business Award on Jun 11, 2025. MBRIF also spotlighted the company in an August 2025 feature about startups working on health systems. Together, these events mark a shift from early financing toward accelerator support and public recognition. The available profile does not provide hiring trends, deployment numbers, revenue, clinical trial results, or dated product launches, so it is not possible to determine whether these milestones translated into faster commercial growth. Funding totals also require care: the selected company total is $642,332, while the listed 2024 extension is additional and its amount is not reflected in that total.